Major Depressive Disorder - Market Insight, Epidemiology, and Market Forecast - 2036

Major Depressive Disorder (MDD) Insights and Trends

• Depression is a common mental health disorder characterized by persistent feelings of sadness, hopelessness, and a loss of interest or pleasure in activities once enjoyed. Also known as major depressive disorder (MDD) or clinical depression, it can significantly affect a person's emotions, thoughts, behaviors, and overall functioning, often leading to a range of emotional, cognitive, and physical symptoms that impact daily life.
• The growing prevalence of depression, increasing mental health awareness, and improved psychiatric screening practices are contributing to a rising diagnosed patient pool across the globe.
• MDD is more prevalent in females (~65%) than males in US in 2025.
• There were more than 10 million females and nearly 7 million males among the gender-specific diagnosed prevalent cases of MDD in EU4 and the UK in 2025.
• According to World Health Organization (2025), an estimated 5.7% of adults suffer from depression, globally.
• Diagnosis of MDD remains largely dependent on subjective clinical assessments and patient-reported symptoms rather than definitive biological tests. The absence of validated biomarkers can lead to delayed diagnosis and misclassification, highlighting the need for more precise and objective diagnostic approaches.
• The MDD market is becoming increasingly competitive with the availability of novel mechanism-based therapies beyond traditional SSRIs and SNRIs. Approved therapies such as Esketamine (SPRAVATO), Dextromethorphan and bupropion (AUVELITY), and Lumateperone (CAPLYTA), among others are intensifying competition based on rapid efficacy, tolerability, route of administration, and long-term symptom control.
• Esketamine (SPRAVATO) continues to lead the novel MDD therapy segment and remains the highest-revenue product among recently approved antidepressants.
• Lumateperone (CAPLYTA) is gaining attention due to its differentiated pharmacological profile and favorable tolerability, particularly with respect to metabolic and extrapyramidal adverse effects compared with many atypical antipsychotics.
• The MDD pipeline remains robust and commercially attractive, with major pharmaceutical and biotechnology companies increasingly investing in novel neuropsychiatric mechanisms. Companies such as Johnson & Johnson (Seltorexant), Xenon Pharmaceuticals (Azetukalner), and VistaGen (Itruvone (PH10)) are actively expanding the innovation landscape through development programs targeting glutamatergic signaling, orexin pathways, and neurocircuit modulation, which are expected to support long-term market growth and competitive diversification in MDD.

DelveInsight's 'Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the MDD, historical and forecasted epidemiology, as well as the MDD market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The MDD market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates MDD patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in MDD and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Major Depressive Disorder (MDD) Market

Rising Prevalence of Depression and Mental Health Awareness

The increasing global burden of depression, along with growing public awareness regarding mental health, is driving higher diagnosis and treatment rates. Reduced social stigma and expanding mental health advocacy initiatives are further encouraging patients to seek medical care earlier.

Growing Demand for Rapid-Acting Antidepressants

Conventional antidepressants often require several weeks to show clinical benefit, creating strong demand for faster-acting therapies. The success of novel agents such as NMDA receptor modulators and intranasal therapies is accelerating market growth and therapeutic innovation.

Increasing Research and Pipeline Innovation

Pharmaceutical companies are actively developing next-generation antidepressants with improved efficacy, safety, and tolerability profiles. Emerging drug classes including orexin receptor antagonists, neuroactive pherines, and multimodal modulators are expanding the future treatment landscape.

Major Depressive Disorder (MDD) Understanding and Treatment Algorithm

Major Depressive Disorder (MDD) Overview and Diagnosis

MDD is a chronic and debilitating psychiatric disorder characterized by persistent feelings of sadness, loss of interest or pleasure in daily activities, low energy, impaired concentration, sleep disturbances, appetite changes, and feelings of worthlessness or hopelessness. The condition can substantially impair social, occupational, and cognitive functioning and, in severe cases, may lead to suicidal ideation or self-harm. MDD is considered a multifactorial disorder influenced by genetic susceptibility, neurochemical imbalances, psychosocial stressors, inflammation, and alterations in neural circuitry involving serotonergic, dopaminergic, glutamatergic, and stress-response pathways. It represents one of the leading causes of disability worldwide and poses a significant public health and economic burden.

Diagnosis of MDD is primarily based on clinical evaluation and psychiatric assessment using standardized diagnostic criteria such as those outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Patients typically present with depressive symptoms lasting for at least two weeks, including depressed mood, diminished interest, fatigue, sleep abnormalities, psychomotor changes, impaired cognition, and suicidal thoughts. Clinicians may utilize validated screening tools such as the Patient Health Questionnaire-9 (PHQ-9), Hamilton Depression Rating Scale (HAM-D), and Montgomery-Asberg Depression Rating Scale (MADRS) to assess symptom severity and monitor treatment response. Since no definitive laboratory biomarker currently exists for MDD, diagnosis largely relies on symptom evaluation, medical history, and exclusion of other psychiatric or medical conditions.

Current Major Depressive Disorder (MDD) Treatment Landscape

Treatment of MDD involves a combination of pharmacological, psychological, and supportive interventions tailored to disease severity and patient-specific needs. First-line pharmacotherapy commonly includes selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, and psychotherapy approaches such as cognitive behavioral therapy (CBT). In patients with treatment-resistant depression (TRD), newer therapies including esketamine (SPRAVATO), dextromethorphan and bupropion (AUVELITY), and lumateperone (CAPLYTA) are expanding treatment options through novel mechanisms targeting glutamatergic and multimodal neurotransmitter pathways. Additional interventions such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), lifestyle modification, and digital mental health support may also play an important role in comprehensive disease management.

Major Depressive Disorder (MDD) Unmet Needs

The section "unmet needs of MDD" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Delayed onset of action of conventional antidepressants

2. High rates of treatment resistance

3. Safety, tolerability, and adherence challenges

4. Incomplete symptom resolution and residual symptoms, and others.....

Major Depressive Disorder (MDD) Epidemiology

Key Findings from MDD Epidemiological Analysis and Forecast

• As per DelveInsight analysis, the total diagnosed prevalent cases of MDD in the 7MM were found to be ~44 million cases in 2025, which are expected to increase during the forecast period.
• In 2025, the US accounted for the highest diagnosed prevalent cases of MDD in the 7MM with ~22 million cases.
• Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of MDD in 2025, followed by UK, while Spain reported the lowest cases.
• Based on severity, moderate severity cases of MDD were the highest ~40% followed by severe cases and mild cases in the US.

Major Depressive Disorder (MDD) Drug Analysis & Competitive Landscape

The MDD drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase III/II clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the MDD treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the MDD therapeutics market.

Approved Therapies for Major Depressive Disorder (MDD)

Lumateperone (CAPLYTA): Johnson & Johnson

Lumateperone is an atypical antipsychotic. The drug is approved for schizophrenia and bipolar depression and recently expanded into MDD as an adjunctive therapy with antidepressants. Lumateperone modulates serotonin, dopamine, and glutamate neurotransmission pathways, offering antidepressant efficacy with a comparatively favorable metabolic and tolerability profile. Its differentiated mechanism and broad neuropsychiatric potential are expected to strengthen Johnson & Johnson's position in the depression and CNS therapeutics market.

Esketamine (SPRAVATO): Johnson & Johnson

Esketamine is the first N-Methyl-D-Aspartate (NMDA) receptor antagonist nasal spray approved for TRD and MDD with acute suicidal ideation or behavior. The therapy has gained significant market attention due to its novel mechanism, rapid onset of action, and expansion into standalone use for TRD, supported by specialized treatment-center partnerships and REMS-based administration programs.

Major Depressive Disorder (MDD) Key Players, Market Leaders and Emerging Companies

• Johnson & Johnson
• Axsome Therapeutics
• Xenon Pharmaceuticals
• VistaGen, and others

Major Depressive Disorder (MDD) Drug Updates

• In May 2026, Xenon Pharmaceuticals in its Q1 2026 financial stated five additional Phase III studies of azetukalner continue to enroll in epilepsy and depression indications with Phase III X-NOVA2 MDD topline data expected in H1 2027.
• In May 2026, Johnson & Johnson announced presentation of new and encore data from the company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) annual meeting and the American Society of Clinical Psychopharmacology (ASCP) annual meeting.The oral presentation will showcase key data from Phase III studies of seltorexant.
• In April 2026, Johnson & Johnson announced that lumateperone (CAPLYTA) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis.
• In April 2026, Johnson & Johnson announced that the US FDA has approved a supplemental New Drug Application (sNDA) based on long-term data evaluating the safety and efficacy of lumateperone (CAPLYTA) for the prevention of relapse in schizophrenia.
• In September 2025, Johnson & Johnson announced results from the Phase III (MDD3005) 26-week clinical trial evaluating the efficacy and safety of seltorexant compared to quetiapine extended release (XR) as an adjunctive treatment in adult and elderly patients with MDD with insomnia symptoms. Seltorexant and quetiapine XR showed large and clinically meaningful improvements in depressive symptoms.
• In June 2025, Johnson & Johnson announced that the US FDA approved lumateperone (CAPLYTA) as an adjunctive therapy with antidepressants for the treatment of MDD in adults.
• In April 2025, Johnson & Johnson announced that it has completed its acquisition of Intra-Cellular Therapies. With the acquisition, Johnson & Johnson added lumateperone (CAPLYTA) to its portfolio of differentiated medicines.
• In January 2025, Johnson & Johnson announced the US FDA approval of a sNDA for esketamine (SPRAVATO) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with MDD who have had an inadequate response to at least two oral antidepressants.

Major Depressive Disorder (MDD) Market Outlook

The MDD market is undergoing a major shift with the emergence of rapid-acting and mechanistically differentiated therapies beyond traditional SSRIs and SNRIs. Approved therapies such as lumateperone (CAPLYTA), esketamine (SPRAVATO), and dextromethorphan and bupropion (AUVELITY) have expanded treatment options for patients with TRD and inadequate response to conventional antidepressants. Esketamine continues to strengthen its market position due to its rapid antidepressant effects and growing clinical adoption, while dextromethorphan and bupropion offers a convenient oral therapy with faster symptom improvement compared with standard antidepressants. Lumateperone is also gaining attention owing to its favorable tolerability profile and multimodal activity involving serotonergic, dopaminergic, and glutamatergic pathways.

Investigational candidates including Seltorexant, Azetukalner, and Itruvone (PH10) are being developed to improve efficacy, onset of action, and tolerability in patients with persistent depressive symptoms. Seltorexant, may provide additional benefits in MDD patients with insomnia through selective OX2 receptor antagonism. Azetukalner is being explored for its modulation of glutamatergic neurotransmission and synaptic plasticity. Meanwhile, Itruvone (PH10), an intranasal neuroactive pherine therapy, has received FDA Fast Track designation (FTD) for MDD, highlighting its potential as a rapid-acting antidepressant with a differentiated safety profile and novel mechanism targeting olfactory-amygdala neural circuits.

• Among the 7MM, the US accounted for the largest market size of MDD, i.e., USD ~6,100 million in 2025 and is projected to grow at a significant CAGR through 2036.
• Germany account for the highest market size of MDD, among EU4 and the UK in 2025.
• While selective serotonin reuptake inhibitors remain the standard first-line treatment, a substantial proportion of patients exhibit inadequate treatment responses or discontinue therapy because of adverse effects, highlighting the need for innovative therapeutic approaches.
• Antidepressants are the cornerstone of MDD treatment. However, more than half of patients do not respond to first-line antidepressants, and many fail to achieve remission or even a clinical response after two or more adequate antidepressant trials, a condition known as TRD.
• Johnson & Johnson is well-positioned to remain a key market leader in MDD, supported by a robust portfolio that includes two approved therapies, esketamine and lumateperone, and the late-stage candidate, seltorexant. This diversified presence enables the company to address a broad spectrum of patient needs, from TRD to patients with coexisting sleep disturbances, while creating multiple revenue streams and strengthening its competitive position against emerging market entrants.

Drug Class/Insights into Leading Emerging and Marketed Therapies in MDD (2022-2036 Forecast)

The MDD market (2022-2036 forecast) is evolving toward mechanism-based therapies that address underlying neurobiological dysfunctions beyond traditional monoaminergic antidepressants. Pathways involved are glutamatergic modulation, orexin signaling, and neurocircuit-based therapies.

• NMDA Receptor Antagonists/Glutamatergic Modulators: Approved therapies such as esketamine (SPRAVATO) and dextromethorphan and bupropion (AUVELITY) are redefining the treatment landscape through modulation of glutamatergic neurotransmission, enabling rapid antidepressant effects compared with conventional SSRIs and SNRIs. Emerging glutamatergic agents such as azetukalner are further being explored to enhance synaptic plasticity and neuronal signaling.
• Orexin-2 Receptor Antagonist: Emerging drug candidate Seltorexant is being developed as a selective orexin-2 receptor antagonist to address depressive symptoms associated with insomnia and sleep disturbances, reflecting growing interest in sleep-related neurobiology in MDD management.

Major Depressive Disorder (MDD) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the MDD drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Among approved therapies, esketamine is expected to maintain its leadership position, supported by strong commercial performance based on 2025 sales, established use in TRD, and continued physician adoption despite the administration and monitoring requirements associated with its use. Meanwhile, dextromethorphan-bupropion is emerging as one of the fastest-growing therapies in the MDD market owing to its convenient oral formulation, rapid onset of antidepressant effects, and strong sales momentum. Esketamine currently dominates in terms of revenue generation and clinical establishment. Dextromethorphan-bupropion is demonstrating the strongest growth momentum and market expansion, while lumateperone is carving out a differentiated niche based on tolerability and broad psychiatric utility.

Among emerging therapies, seltorexant is expected to demonstrate moderate-to-strong uptake potential, particularly in MDD patients with insomnia and sleep-related symptoms, reflecting growing interest in orexin-targeted therapies. Azetukalner may attract attention as a next-generation glutamatergic modulator designed to improve synaptic function and depressive symptoms. Meanwhile, Itruvone (PH10) is projected to experience gradual uptake if approved, supported by its rapid-acting intranasal delivery approach and FTD, although long-term clinical validation and commercialization dynamics may influence adoption trends.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Major Depressive Disorder (MDD)

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Major Depressive Disorder (MDD) Therapies Price Scenario & Trends

Pricing and analogue assessment of MDD therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Major Depressive Disorder (MDD)

To keep up with MDD market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the MDD emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in MDD, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at the country level. Centers such as Robert Koch Institute, King's College, and UC Irvine Depression Institute, etc. were contacted.Their opinion helps understand and validate current and emerging MDD therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in MDD.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of MDD, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of MDD, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the MDD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM MDD market.

Report Insights

• Major Depressive Disorder (MDD) Patient Population Forecast
• Major Depressive Disorder (MDD) Therapeutics Market Size
• Major Depressive Disorder (MDD) Pipeline Analysis
• Major Depressive Disorder (MDD) Market Size and Trends
• Major Depressive Disorder (MDD) Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Major Depressive Disorder (MDD) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Major Depressive Disorder (MDD) Treatment Addressable Market (TAM)
• Major Depressive Disorder (MDD) Competitive Landscape
• Major Depressive Disorder (MDD) Major Companies Insights
• Major Depressive Disorder (MDD) Price Trends and Analogue Assessment
• Major Depressive Disorder (MDD) Therapies Drug Adoption/Uptake
• Major Depressive Disorder (MDD) Therapies Peak Patient Share Analysis

Report Assessment

• Major Depressive Disorder (MDD) Current Treatment Practices
• Major Depressive Disorder (MDD) Unmet Needs
• Major Depressive Disorder (MDD) Clinical Development Analysis
• Major Depressive Disorder (MDD) Emerging Drugs Product Profiles
• Major Depressive Disorder (MDD) Market attractiveness
• Major Depressive Disorder (MDD) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the MDD market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of MDD?
• What are the disease risks, burdens, and unmet needs of MDD? What will be the growth opportunities across the 7MM concerning the patient population with MDD?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of MDD? What are the current guidelines for treating MDD in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the MDD market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.